Hangzhou Jiayin Biotech Inaugurates GMP R&D Facility and Enters Strategic Partnership with Wenzhou Medical University

VCBeat has learned that on June 30, 2020, Hangzhou Jiayin Biotechnology Co., Ltd. (hereinafter referred to as “Hangzhou Jiayin Biotech”) held a completion ceremony for its GMP production and R&D platform, alongside the signing ceremony of the strategic cooperation agreement between Hangzhou Jiayin Biotech and Wenzhou Medical University. Leaders from the Hangzhou Medicine Port Town and Dachuang Town Development Service Center, officials from the Economic Development and Science & Technology Bureau, the founder of Caitai Capital, the Managing Director of Legend Capital, the General Manager of Sinopharm Qibeide, representatives from Wenzhou Medical University, the founder of Hangzhou Jiayin Biotech, and partners of the company gathered at Medicine Port Town to witness this significant event.

Ribbon-Cutting Ceremony for the GMP Production and R&D Platform of Hangzhou Jiayin Biotechnology. Ribbon-Cutting Guests (from left to right): Wang Yunbao, Wang Lijun, Ye Guojie, Wu Zhenhua, Xu Yonghong, Wang Junfeng, Tao Feng

Hangzhou Jiayin Biopharma, established in July 2019, is a pharmaceutical company dedicated to the field of gene therapy, with robust GMP-compliant large-scale manufacturing capabilities. Since its inception, the company has achieved rapid growth, assembling a core team with comprehensive expertise and hands-on experience in R&D, process development, and manufacturing—a rarity among Chinese gene therapy firms. Backed by substantial technological reserves, Hangzhou Jiayin Biopharma is poised to evolve into an internationally innovative and influential gene therapy company, eventually entering European and American markets to compete with multinational corporations (MNCs). The company’s vision is to conquer intractable diseases by providing epoch-making, one-time curative, safe, effective, and affordable gene therapy medicines for patients.

Welcome Address by Wu Zhenhua, Founder and CEO of Hangzhou Jiayin Biotechnology Co., Ltd.

At the ceremony, Wu Zhenhua, Founder and CEO of Hangzhou Jiayin Biotechnology Co., Ltd., stated, “Gene and cell therapy represents the latest biotherapeutic approach in the global pharmaceutical industry. Related research and manufacturing in Europe and the United States have entered a phase of rapid expansion, with multiple products already approved for marketing abroad. In contrast, China’s gene therapy industry remains in its early stages of development. To gradually close the gap with international counterparts, China’s gene therapy sector requires substantial investment across knowledge, technology, talent, and capital. On January 9, 2020, Hangzhou Jiayin Biotechnology took a solid first step in this field by officially commencing construction of its gene therapy R&D and GMP manufacturing platform. With the guidance and support of governments at all levels, the project was completed today. The future mission of Jiayin Biotechnology is both significant and challenging. We have established here the most comprehensive gene therapy production and management system in China, compliant with cGMP standards in China, the United States, and Europe.”

Hangzhou Jiayin Biologics’ Gene Therapy R&D and cGMP Manufacturing Platform Covers an Area of Approximately 1,700 m²², with a total of 4 floors and a building area of 6,000 m²², with integrated gene therapy drug R&D and GMP manufacturing facilities, it can effectively address the challenges facing gene therapy research in China. Upholding its responsibility and mission to improve human health, Hangzhou Jiayin Biotechnology will usher in a new chapter for gene therapy R&D and GMP production in China.

Since its establishment in July 2019, Hangzhou Jiayin Biotechnology has relied on the support and assistance of the government. Tao Feng, Director of the Hangzhou Medical Port Town Development Service Center, stated on-site that strong policy support would be provided to Hangzhou Jiayin Biotechnology. Xu Yonghong, Founder and CEO of Cathay Capital, and Wang Junfeng, Managing Director at Legend Capital, delivered speeches at the event. They both noted that Jiayin Biotechnology, founded by a team of overseas-returning entrepreneurs, has effectively integrated scarce talent resources within the industry. With extensive experience and first-mover advantages in production and operations, the company is well-positioned to enhance its success rate in a rapidly competitive environment, with the potential to quickly become a leading player in China and rapidly catch up with international counterparts.

Hangzhou Jiayin Biotechnology Co., Ltd. Signs Strategic Cooperation Agreement with Representatives of Wenzhou Medical University

Hangzhou Jiayin Biotechnology Co., Ltd. and Wenzhou Medical University Zhejiang Gene Medicine Valley Management Co., Ltd., leveraging the complementary strengths of their respective platforms, hereby establish a long-term and comprehensive strategic partnership. The parties aim to jointly explore new models of business development, enhance market competitiveness, achieve resource sharing and mutual growth, and lay a solid foundation for future collaboration on other projects.

Li Xiaokun, President of Wenzhou Medical University and Academician of the Chinese Academy of Engineering, extended warm congratulations on the launch of Hangzhou Jiayin Biotechnology Co., Ltd.’s advanced GMP manufacturing and R&D platform for biotherapeutic drugs. He stated, “The 21st century is an era marked by significant developments and breakthroughs in biomedicine. In recent years, the field of gene therapy has witnessed rapid growth, while also facing challenges such as high technical barriers and prohibitive treatment costs. Against this backdrop, it is of great significance that Dr. Wu Zhenhua and his team have returned to China to establish Jiayin Biotechnology and engage in the research and development of gene therapy drugs. Wenzhou Medical University boasts a comprehensive team dedicated to the R&D of cytokine-based pharmaceuticals. We look forward to the collaboration between Jiayin Biotechnology and Wenzhou Medical University in integrating cytokine technologies with gene therapy techniques, anticipating that this synergy will spark new innovations.”